Literature DB >> 25393420

Short telomeres, telomeropathy, and subclinical extrapulmonary organ damage in patients with interstitial lung disease.

Gautam George1, Ivan O Rosas1, Ye Cui1, Caitlin McKane1, Gary M Hunninghake1, Phillip C Camp2, Benjamin A Raby3, Hilary J Goldberg1, Souheil El-Chemaly4.   

Abstract

BACKGROUND: Human telomere disease consists of a wide spectrum of disorders, including pulmonary, hepatic, and bone marrow abnormalities. The extent of bone marrow and liver abnormalities in patients with interstitial lung disease (ILD) and short telomeres is unknown.
METHODS: The lung transplant clinic established a prospective protocol to identify short telomeres in patients with ILD not related to connective tissue disease or sarcoidosis. Patients with short telomeres underwent bone marrow biopsies, liver biopsies, or both as part of the evaluation for transplant candidacy.
RESULTS: One hundred twenty-seven patients met ILD categorization for inclusion. Thirty were suspected to have short telomeres, and 15 had the diagnosis confirmed. Eight of 13 (53%) patients had bone marrow abnormalities. Four patients had hypocellular marrow associated with macrocytosis and relatively normal blood counts, which resulted in changes to planned immunosuppression at the time of transplant. Four patients with more severe hematologic abnormalities were not listed because of myelodysplastic syndrome (two); monoclonal gammopathy of unclear significance (one); and hypocellular marrow, decreased megakaryocyte lineage associated with thrombocytopenia (one). Seven patients underwent liver biopsies, and six had abnormal liver pathology. These abnormalities did not affect listing for lung transplant, and liver biopsies are no longer routinely obtained.
CONCLUSIONS: Subclinical bone marrow and liver abnormalities can be seen in patients with ILD and short telomeres, in some cases in the absence of clinically significant abnormalities in peripheral blood counts and liver function tests. A larger study examining the implication of these findings on the outcome of patients with ILD and short telomeres is needed.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25393420      PMCID: PMC4451709          DOI: 10.1378/chest.14-0631

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  25 in total

1.  Poor outcomes associated with neutropenia after kidney transplantation: analysis of United States Renal Data System.

Authors:  Frank P Hurst; Pallavi Belur; Robert Nee; Lawrence Y Agodoa; Purav Patel; Kevin C Abbott; Rahul M Jindal
Journal:  Transplantation       Date:  2011-07-15       Impact factor: 4.939

2.  Telomere length is a determinant of emphysema susceptibility.

Authors:  Jonathan K Alder; Nini Guo; Frant Kembou; Erin M Parry; Collin J Anderson; Amany I Gorgy; Michael F Walsh; Thomas Sussan; Shyam Biswal; Wayne Mitzner; Rubin M Tuder; Mary Armanios
Journal:  Am J Respir Crit Care Med       Date:  2011-07-14       Impact factor: 21.405

3.  Subclinical lung disease, macrocytosis, and premature graying in kindreds with telomerase (TERT) mutations.

Authors:  Alberto Diaz de Leon; Jennifer T Cronkhite; Cuneyt Yilmaz; Cecelia Brewington; Richard Wang; Chao Xing; Connie C W Hsia; Christine Kim Garcia
Journal:  Chest       Date:  2011-02-24       Impact factor: 9.410

4.  Natural history of pulmonary fibrosis in two subjects with the same telomerase mutation.

Authors:  Souheil El-Chemaly; Shira G Ziegler; Rodrigo T Calado; Kirkland A Wilson; Hai Ping Wu; Mary Haughey; Nathan R Peterson; Neal S Young; William A Gahl; Joel Moss; Bernadette R Gochuico
Journal:  Chest       Date:  2010-10-21       Impact factor: 9.410

Review 5.  Telomere diseases.

Authors:  Rodrigo T Calado; Neal S Young
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245

6.  Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations.

Authors:  Alberto Diaz de Leon; Jennifer T Cronkhite; Anna-Luise A Katzenstein; J David Godwin; Ganesh Raghu; Craig S Glazer; Randall L Rosenblatt; Carlos E Girod; Edward R Garrity; Chao Xing; Christine Kim Garcia
Journal:  PLoS One       Date:  2010-05-19       Impact factor: 3.240

7.  Familial idiopathic pulmonary fibrosis in association with bone marrow hypoplasia and hepatic nodular regenerative hyperplasia: a new "trimorphic" syndrome.

Authors:  A Talbot-Smith; W-K Syn; G MacQuillan; D Neil; E Elias; P Ryan
Journal:  Thorax       Date:  2009-05       Impact factor: 9.139

8.  Adult-onset pulmonary fibrosis caused by mutations in telomerase.

Authors:  Kalliopi D Tsakiri; Jennifer T Cronkhite; Phillip J Kuan; Chao Xing; Ganesh Raghu; Jonathan C Weissler; Randall L Rosenblatt; Jerry W Shay; Christine Kim Garcia
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-25       Impact factor: 11.205

9.  Short telomeres are a risk factor for idiopathic pulmonary fibrosis.

Authors:  Jonathan K Alder; Julian J-L Chen; Lisa Lancaster; Sonye Danoff; Shu-chih Su; Joy D Cogan; Irma Vulto; Mingyi Xie; Xiaodong Qi; Rubin M Tuder; John A Phillips; Peter M Lansdorp; James E Loyd; Mary Y Armanios
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-27       Impact factor: 11.205

10.  A spectrum of severe familial liver disorders associate with telomerase mutations.

Authors:  Rodrigo T Calado; Joshua A Regal; David E Kleiner; David S Schrump; Nathan R Peterson; Veronica Pons; Stephen J Chanock; Peter M Lansdorp; Neal S Young
Journal:  PLoS One       Date:  2009-11-20       Impact factor: 3.240

View more
  19 in total

1.  Running short on time: lung transplant evaluation for telomere-related pulmonary fibrosis.

Authors:  Christine Kim Garcia
Journal:  Chest       Date:  2015-06       Impact factor: 9.410

Review 2.  Telomeres in Interstitial Lung Disease: The Short and the Long of It.

Authors:  Andrew M Courtwright; Souheil El-Chemaly
Journal:  Ann Am Thorac Soc       Date:  2019-02

3.  Genetic Evaluation and Testing of Patients and Families with Idiopathic Pulmonary Fibrosis.

Authors:  Jonathan A Kropski; Lisa R Young; Joy D Cogan; Daphne B Mitchell; Lisa H Lancaster; John A Worrell; Cheryl Markin; Na Liu; Wendi R Mason; Tasha E Fingerlin; David A Schwartz; William E Lawson; Timothy S Blackwell; John A Phillips; James E Loyd
Journal:  Am J Respir Crit Care Med       Date:  2017-06-01       Impact factor: 21.405

Review 4.  Insights from human genetic studies of lung and organ fibrosis.

Authors:  Christine Kim Garcia
Journal:  J Clin Invest       Date:  2018-01-02       Impact factor: 14.808

Review 5.  Pulmonary fibrosis in the era of stratified medicine.

Authors:  Susan K Mathai; Chad A Newton; David A Schwartz; Christine Kim Garcia
Journal:  Thorax       Date:  2016-10-31       Impact factor: 9.139

6.  Telomere biology disorder prevalence and phenotypes in adults with familial hematologic and/or pulmonary presentations.

Authors:  Simone Feurstein; Ayodeji Adegunsoye; Danijela Mojsilovic; Rekha Vij; Allison H West DePersia; Padma Sheila Rajagopal; Afaf Osman; Robert H Collins; Raymond H Kim; Steven D Gore; Peter Greenberg; Lucy A Godley; Zejuan Li; Daniela Del Gaudio; Hari Prasanna Subramanian; Soma Das; Tom Walsh; Suleyman Gulsuner; Jeremy P Segal; Aliya N Husain; Sandeep Gurbuxani; Mary-Claire King; Mary E Strek; Jane E Churpek
Journal:  Blood Adv       Date:  2020-10-13

7.  The Spectrum of Hepatic Involvement in Patients With Telomere Disease.

Authors:  Devika Kapuria; Gil Ben-Yakov; Rebecca Ortolano; Min Ho Cho; Or Kalchiem-Dekel; Varun Takyar; Shilpa Lingala; Naveen Gara; Michele Tana; Yun Ju Kim; David E Kleiner; Neal S Young; Danielle M Townsley; Christopher Koh; Theo Heller
Journal:  Hepatology       Date:  2019-04-10       Impact factor: 17.425

8.  Clinical outcomes of lung transplant recipients with telomerase mutations.

Authors:  Sofya Tokman; Jonathan P Singer; Megan S Devine; Glen P Westall; John-David Aubert; Michael Tamm; Gregory I Snell; Joyce S Lee; Hilary J Goldberg; Jasleen Kukreja; Jeffrey A Golden; Lorriana E Leard; Christine K Garcia; Steven R Hays
Journal:  J Heart Lung Transplant       Date:  2015-05-11       Impact factor: 10.247

9.  IPF lung fibroblasts have a senescent phenotype.

Authors:  Diana Álvarez; Nayra Cárdenes; Jacobo Sellarés; Marta Bueno; Catherine Corey; Vidya Sagar Hanumanthu; Yating Peng; Hannah D'Cunha; John Sembrat; Mehdi Nouraie; Swaroop Shanker; Chandler Caufield; Sruti Shiva; Mary Armanios; Ana L Mora; Mauricio Rojas
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-08-31       Impact factor: 5.464

10.  Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive.

Authors:  Chad A Newton; Kiran Batra; Jose Torrealba; Julia Kozlitina; Craig S Glazer; Carlos Aravena; Keith Meyer; Ganesh Raghu; Harold R Collard; Christine Kim Garcia
Journal:  Eur Respir J       Date:  2016-08-18       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.